CD33 and acute lymphoblastic leukemia: The total 15 events (32.6%) of occurrence of aberrant antigen markers were seen in T-ALL including CD10 (20%), CD13 (13.3%), CD33 (6.6%), CD79a (6.6%), CD117 and HLA-DR (26.6% each).